Why Galena Biopharma Inc. Stock Tumbled

Galena stock is a big loser after the company fails to impress with its second-quarter earnings results.

Aug 12, 2014 at 1:01PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company focused on developing immunotherapies to treat cancer, tumbled by as much as 16% after the company reported its second-quarter earnings results.

So what: For the quarter, Galena reported $2.3 million in revenue from Abstral, its cancer pain medication acquired from Orexo last year, compared to no revenue recorded in the year-ago period. Operating loss, however, ballooned to $15.8 million, including stock-based compensation charges, from $11.8 million in the year-ago quarter. On a per share basis this worked out to a loss of $0.17 when Wall Street was looking for a much narrower loss of $0.09 per share. Galena ended the quarter with $39.2 million in cash, which is down from $47.8 million as of the end of December.


Source: Galena Biopharma.

Now what: Usually earnings reports for predominantly clinical-stage biopharmaceutical companies tend to not move a company's stock as much as we've witnessed Galena move today. However, the results of Galena's phase 3 study of lead drug NeuVax, its adjuvant breast cancer vaccine aimed at preventing or delaying the rate of recurrence, is still a ways out, so Galena's cash burn continues to come into play.

In addition, the quick start to Abstral -- $2.2 million in revenue in Q1 -- gave hope to investors that Galena could see meaningful revenue recognition sooner rather than later which it might use to offset the high costs associated with running a phase 3 study. However, Abstral's minimal quarter-over-quarter sales improvement (just $0.1 million) pretty much took that thesis off the table for the time being.

Overall, I still believe Galena represents an intriguing story stock considering the success of NeuVax in phase 2 studies and the potential behind immunotherapies, which retrain a person's immune system to locate and attack cancer. However, I'm also not blind to the fact that Galena is burning cash and is expected to lose money for the foreseeable future. Long story short, I'm staying firmly perched on the sidelines.

NeuVax may offer plenty of potential, but this revolutionary new technology could end up leaving it in the dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information